-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
Cutaneous T-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
Metastatic Adenocarcinoma of The Pancreas - Drugs In Development, 2024
Empower your strategies with our Metastatic Adenocarcinoma of The Pancreas – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic adenocarcinoma is a cancer that originates in glandular cells (mucus-secreting cells) such as milk ducts, the digestive tract, or lungs and has spread or metastasized beyond the tissue in which it began. Adenocarcinomas can spread at any stage of the disease or they can lay dormant for an extended period of time before recurring in a distant location....
-
Product Insights
Anal Cancer - Drugs In Development, 2024
Empower your strategies with our Anal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity. The Anal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Anal...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer - Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. Human papillomavirus (HPV)-associated cancer has no symptoms until it is quite advanced, very serious, and hard to treat....
-
Product Insights
Metastatic Hepatocellular Carcinoma (HCC) - Drugs In Development, 2024
Empower your strategies with our Metastatic Hepatocellular Carcinoma (HCC) – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic hepatocellular carcinoma (HCC) refers to liver cancer that has spread to other parts of the body. It originates in liver cells and often spreads to the lungs, bones, lymph nodes, or other organs. Symptoms at this stage can include jaundice, abdominal pain, weight loss, and fatigue. Treatment options for metastatic HCC involve a combination of therapies, such as targeted...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2024
Empower your strategies with our Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a...
-
Product Insights
Ewing Sarcoma - Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...
-
Product Insights
Malignant Pleural Mesothelioma - Drugs In Development, 2024
Empower your strategies with our Malignant Pleural Mesothelioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant pleural mesothelioma is a rare cancer of the lining around the lungs, called the pleura. It is caused by asbestos fibers. After inhalation, the fibers can embed in the pleura, causing inflammation and scarring. Over time, these processes can lead to the development of mesothelioma tumors. The most common symptoms of pleural mesothelioma include difficulty breathing, swelling, back pain, and...
-
Product Insights
High-Grade Glioma - Drugs In Development, 2024
Empower your strategies with our High-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy. The High-Grade Glioma drugs in development market research report provide...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.